Radar · Life Sciences in China
Best Life Sciences Companies in China
The 1538 best Life Sciences companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
By Rohit KhannaTrends & Stories
1538companies tracked
$33.5Bdisclosed funding
8unicorns
686have raised
Life Sciences in China is moving fast, and this directory ranks 1,538 companies by disclosed equity funding and recent momentum to show you exactly where the capital is landing.
$33.5B in total disclosed funding. Eight unicorns. Clover Biopharma leads at $400M raised, with D3 Bio at $262M and Ascletis at $255M not far behind. The sector's global market is tracking toward a ~10.2% CAGR, and the China cohort here reflects that pull clearly. Qiming Venture Partners, Hillhouse, and Lilly Asia Ventures are the names showing up most consistently across deal tables, which tells you something about where conviction is concentrating. I'd watch OriCell Therapeutics ($170M) closely given where cell-based therapies sit in the current cycle.
Coverage is flat, but the hot themes are anything but. Stem cell banking, gene delivery systems, and diagnostic biotechnology are drawing the most attention this quarter. And with TPG backing Sai Life Sciences toward an IPO and Asahi Songwon moving into the API business via acquisition, the broader signal is clear: consolidation and public-market ambition are both accelerating. What's the common thread? Capital chasing scale before the next regulatory window opens.
Sources & further reading
- The complexity of the pharma supply chain
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
- India's CDMO market set to double by 2028 amid Asia's healthcare boom
FLIAR INTELLIGENCE · LIFE SCIENCES × CHINA
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
71kcombined LinkedIn audience
30%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in China
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | Dr InBev Co-Founder & Co-CEO | — | Animate.cssjQueryHSTS | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Clover Biopharma Developer of drugs to treat autoimmune, cancer and infectious diseases 67Funding top 13%Market top 25%Global top 44%Moat top 48% All 6 signals ▾Fundingtop 13% Markettop 25% Globaltop 44% Moattop 48% Newsbottom 32% Techbottom 24% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom rank vs industry peers · Fliar Intelligence Index 67/100 | $400M | 2 mo ago | Public | — | 681 | — | — | — |
| 3 | Tianjing Biological Developer of immuno-oncology drugs for treating cancer and autoimmune diseases 55Funding top 21%Market top 41%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 21% Markettop 41% Moattop 48% Talentbottom 49% Globalbottom 46% Techbottom 45% Newsbottom 21% Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property rank vs industry peers · Fliar Intelligence Index 55/100 | $380M | 28 mo ago | Public | Yan Jingwu Chairman & CEO | 318 | DrupalPHPZURB Foundation+20 | — | — |
| 4 | Avistone Developer of precision therapeutics for oncology 32Funding top 26%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 26% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $340M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $340M | 29 mo ago | Series B | Shi Hepeng Founder & CEO | — | — | — | — |
| 5 | D3 Bio Developer novel therapeutics for cancer 40Funding top 20%Growth top 35%Talent bottom 49%Moat bottom 48% All 7 signals ▾Fundingtop 20% Growthtop 35% Talentbottom 49% Moatbottom 48% Techbottom 40% Globalbottom 38% Marketbottom 28% Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $262M | 6 mo ago | Series B | George Chen Founder & CEO | — | WebflowMicrosoft 365jQuery+7 | — | — |
| 6 | Ascletis Developer of small molecules for the treatment of multiple diseases 42Funding top 19%Product top 30%Moat top 31%Innovation top 34% All 10 signals ▾Fundingtop 19% Producttop 30% Moattop 31% Innovationtop 34% Talentbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 36% Techbottom 30% Newsbottom 24% Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Product: 6 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 42/100 | $255M | 3 mo ago | Series B | Jinzi Wu Founder & CEO | 41 | PHPJW PlayerBootstrap+6 | — | — |
| 7 | HIBio 🦄 Developer of precision medicines for autoimmune and inflammatory diseases 57Funding top 27%Market top 38%Moat top 47%Talent bottom 49% All 6 signals ▾Fundingtop 27% Markettop 38% Moattop 47% Talentbottom 49% Globalbottom 38% Newsbottom 22% Funding: Raised $215M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Market: 44 employees (top 40% of Life Sciences) · Unicorn (valued $1.8B) rank vs industry peers · Fliar Intelligence Index 57/100 | $215M | 29 mo ago | Acquired | Travis Murdoch Founder & CEO | 44 | — | — | — |
| 8 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 23 mo ago | Series B | — | 300 | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 9 | Akeso Developer of antibody drug conjugates for the treatment of broad spectrum diseases 57Funding top 20%Growth top 35%News top 39%Market top 40% All 8 signals ▾Fundingtop 20% Growthtop 35% Newstop 39% Markettop 40% Moattop 48% Talentbottom 41% Globalbottom 38% Techbottom 35% Funding: Raised $195M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $195M | 20 mo ago | Public | Michelle Xia CEO & President | 2,520 | UmbracoMicrosoft ASP.NETBootstrap+8 | — | 1 launch · 1 award |
| 10 | Cornerstone Robotics Developer of medical robotic devices for rehabilitation and surgery 21Funding top 16%Moat top 31%Talent bottom 49%News bottom 41% All 7 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Newsbottom 41% Globalbottom 38% Marketbottom 28% Techbottom 22% Funding: Raised $189M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 21/100 | $189M | 7 mo ago | Series D | Zerui Wang Co-Founder | — | PHPLayuiGSAP+6 | — | 1 launch |
| 11 | Qi Carbon Technology Developer of single-molecule nanopore sequencing technology 48Moat top 22%Funding top 27%Talent top 41%Growth top 45% All 7 signals ▾Moattop 22% Fundingtop 27% Talenttop 41% Growthtop 45% Markettop 46% Techbottom 34% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $187M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $187M | 29 mo ago | Series C | Jingwei Bai Founder | 270 | Node.jsJavaUbuntu+7 | — | — |
| 12 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 2 mo ago | Series D | He Xiaowen Co-Founder | 150 | — | 56 patents Patents concentrated in health & consumer products | — |
| 13 | Adagene Developer of immunotherapy for the treatment of cancer 37Funding top 18%Product top 24%Moat top 38%Tech top 42% All 12 signals ▾Fundingtop 18% Producttop 24% Moattop 38% Techtop 42% Globaltop 43% Partnerstop 45% Patentstop 46% Talentbottom 49% Growthbottom 42% Innovationbottom 38% Marketbottom 36% Newsbottom 23% Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 37/100 | $157M | 11 mo ago | Public | Peter Luo Founder & CEO | 15 | DrupalPHPZURB Foundation+22 | 26 patents Antibody library engineering and heterodimeric Fc protein therapeutics for cancer treatment | — |
| 14 | Impact Therapeutics Developer of small molecule therapeutics for the treatment of cancer 50Patents top 18%Funding top 21%Innovation top 23%Moat top 26% All 6 signals ▾Patentstop 18% Fundingtop 21% Innovationtop 23% Moattop 26% Globalbottom 43% Marketbottom 26% Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $145M | 19 mo ago | Public | — | 7 | — | 226 patents Small-molecule inhibitors of PARP, kinases, and DHX9 for cancer therapy | — |
| 15 | Ronovo Surgical Developer of robotic surgical instruments 21Funding top 18%Moat top 31%Talent bottom 49%News bottom 42% All 7 signals ▾Fundingtop 18% Moattop 31% Talentbottom 49% Newsbottom 42% Globalbottom 36% Marketbottom 28% Techbottom 24% Funding: Raised $119M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 21/100 | $119M | 9 mo ago | Series D | John Ma Founder & CEO & Chairman | — | Animate.cssMicrosoft ASP.NETLenis+4 | — | — |
| 16 | Immorna Developer of mRNA-based therapeutics for cancer and other diseases 14Funding top 29%Moat top 38%Talent bottom 49%Global bottom 36% All 6 signals ▾Fundingtop 29% Moattop 38% Talentbottom 49% Globalbottom 36% Marketbottom 25% Techbottom 24% Funding: Raised $115M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 14/100 | $115M | 21 mo ago | Series A | Zihao Wang CEO | — | Microsoft ASP.NETBootstrapTengine+3 | — | — |
| 17 | SciNeuro Developer of therapeutic solutions for the treatment of CNS disorders 29Funding top 27%Moat top 31%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Techbottom 45% Globalbottom 36% Marketbottom 33% Funding: Raised $100M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $100M | 6 mo ago | Series A | Min Li Founder & CEO | 22 | WordPressMySQLPHP+23 | — | — |
| 18 | Full-Life Technologies Provider of discovery, development, production, and logistics services for of nuclear medicines 48Funding top 17%Talent top 28%Patents top 33%Growth top 35% All 9 signals ▾Fundingtop 17% Talenttop 28% Patentstop 33% Growthtop 35% Innovationtop 45% Moattop 47% Globalbottom 45% Marketbottom 32% Techbottom 22% Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $94M | 1 mo ago | Series D | HH Ting Co-Founder And Chief Strategy Officer | — | PHPAnimate.cssBootstrap+6 | 24 patents Targeted radiopharmaceuticals and antibody therapeutics for cell‑surface receptors | — |
| 19 | MAXVAX Biotechnology Developer of vaccines for infectious diseases 57Funding top 22%Market top 40%Moat top 42%Talent bottom 49% All 5 signals ▾Fundingtop 22% Markettop 40% Moattop 42% Talentbottom 49% Globalbottom 36% Funding: Raised $84.8M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 57/100 | $85M | 6 mo ago | Series D | Dexiang Chen Founder | 100 | — | — | — |
| 20 | TowardPi Developer of OCT and optical biometers for ophthalmic diseases 55Funding top 29%Growth top 35%Market top 44%Talent bottom 49% All 6 signals ▾Fundingtop 29% Growthtop 35% Markettop 44% Talentbottom 49% Techbottom 43% Globalbottom 29% Funding: Raised $70.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $70M | 23 mo ago | Series D | Yingqi Wang CEO | 240 | JavaBootstrapRequireJS+6 | — | 1 launch |
| 21 | RONA Therapeutics Developer of oligonucleotide therapeutics to treat multiple diseases 40Patents top 31%Moat top 32%Funding top 40%Innovation top 42% All 7 signals ▾Patentstop 31% Moattop 32% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 43% Marketbottom 40% Patents: 27 patents matched (strict assignee match) · 27 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 22 mo ago | Series A | Stella Shi Founder | — | — | 27 patents RNAi therapeutics and targeted siRNA/ dsRNA delivery for disease-modifying gene regulation | — |
| 22 | Prenetics Online platform for genetic and diagnostic health testing that helps identify health risks 67Funding top 22%Tech top 30%News top 31%Talent top 33% All 10 signals ▾Fundingtop 22% Techtop 30% Newstop 31% Talenttop 33% Growthtop 34% Moattop 37% Markettop 38% Globaltop 44% Innovationbottom 34% Patentsbottom 31% Funding: Raised $67.7M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Tech: 51 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 67/100 | $68M | 7 mo ago | Public | Michael Yang Co-Founder And Scientific Advisor | 400 | DrupalApple iCloud MailGoogle Workspace+31 | 8 patents Integrated enzyme pellet platforms for rapid nucleic acid diagnostic testing | — |
| 23 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 1 mo ago | Series C | Xiaohu Zhang Co-Founder & CEO | — | — | — | — |
| 24 | Phrontline Biopharma Developer of therapeutics for various diseases 64Talent top 28%Funding top 29%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 29% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $60M | 6 mo ago | Seed | Siyi Hu Co-Founder | — | — | — | — |
| 25 | Epigenic Therapeutics Developer of gene editing therapies for a wide variety of diseases 57Funding top 26%Patents top 28%Moat top 32%Innovation top 37% All 9 signals ▾Fundingtop 26% Patentstop 28% Moattop 32% Innovationtop 37% AItop 45% Talentbottom 49% Newsbottom 42% Marketbottom 40% Globalbottom 40% Funding: Raised $52.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Patents: 43 patents matched (strict assignee match) · 43 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $52M | 9 mo ago | Series B | Bob Zhang Co-Founder & CEO | — | — | 43 patents Epigenome editing tools for therapeutic gene repression (viral, metabolic, angiogenesis targets). | — |
| 26 | Murren Biotechnology Developer of microbial separation and cultivation technologies 40Moat top 22%Funding top 38%Market top 48%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 38% Markettop 48% Talentbottom 49% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $51M | 23 mo ago | Series C | Jiang Xianzhi Founder & CEO | 50 | — | — | — |
| 27 | DeepWise Developer of AI-based radiology image solutions primarily for cancer diagnosis 72AI top 26%Funding top 30%Market top 35%Moat top 39% All 5 signals ▾AItop 26% Fundingtop 30% Markettop 35% Moattop 39% Globalbottom 36% AI: Classified as an AI company · Product described with: ai-based, deep learning Funding: Raised $46.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $46M | 16 mo ago | Series D | — | 200 | — | — | — |
| 28 | Leman Biotech Develope rof AI-based platform for cancer immunotherapy 21AI top 30%Talent top 38%Funding top 39%Global bottom 29% All 6 signals ▾AItop 30% Talenttop 38% Fundingtop 39% Globalbottom 29% Marketbottom 25% Techbottom 15% AI: Classified as an AI company · Product described with: ai-based Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $43M | 3 mo ago | Series A | Li Tang Co-Founder | — | PHPApache HTTP Servercore-js+1 | — | — |
| 29 | Shize Bio Developer of stem-cell therapies to treat neurodegenerative diseases 42Funding top 33%Growth top 35%Talent top 38%Moat top 48% All 7 signals ▾Fundingtop 33% Growthtop 35% Talenttop 38% Moattop 48% Marketbottom 48% Globalbottom 29% Techbottom 16% Funding: Raised $41.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 42/100 | $42M | 19 mo ago | Series B | Michael Lee Founder & CEO | 100 | PHPLayuiAnimate.css+5 | — | — |
| 30 | Wuhan Ruijian Pharmaceutical Technology Developer of cell therapies to treat neurological and ophthalmological diseases 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $40.0M across 1 rounds · 1 rounds over 7 yrs (0.1/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $40M | 9 mo ago | Series B | Jun Wei Founder & CEO | — | — | — | — |
| 31 | KYinno Provider of engineered cell lines for the discovery of oncology drugs 45Funding top 34%Market top 44%Talent bottom 49%Global bottom 29% All 4 signals ▾Fundingtop 34% Markettop 44% Talentbottom 49% Globalbottom 29% Funding: Raised $35.4M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) Market: 65 employees (top 30% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 45/100 | $35M | 6 mo ago | Series B | Hao Feng Co-Founder & Director | 65 | — | — | 1 launch |
| 32 | Chance Pharmaceuticals Developer of transformative inhalation therapies for pulmonology disorders 37Talent top 28%Funding top 41%Global bottom 38%Market bottom 37% All 5 signals ▾Talenttop 28% Fundingtop 41% Globalbottom 38% Marketbottom 37% Newsbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $31.0M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $31M | 15 mo ago | Series C | Peng Huang Co-Founder | — | — | — | — |
| 33 | RoboCT Technology Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions 50Funding top 36%Market top 42%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 36% Markettop 42% Growthtop 45% Talentbottom 49% Globalbottom 48% Techbottom 35% Funding: Raised $29.4M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Market: 100 employees (top 20% of Life Sciences) · Top-5,000,000 web property rank vs industry peers · Fliar Intelligence Index 50/100 | $29M | 3 mo ago | Series B | Wang Tian Founder & CEO | 100 | Cart FunctionalityPHPLayui+13 | — | 1 partnership |
| 34 | Benyao Technology Robotics and artificial intelligence technology to provide automation solutions 64Funding top 37%Market top 39%AI top 45%Talent bottom 49% All 5 signals ▾Fundingtop 37% Markettop 39% AItop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $29.1M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Market: 100 employees (top 20% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 19 mo ago | Series A | Yang Tang Founder & CEO | 100 | — | — | 3 launchs · 1 partnership |
| 35 | Vivolight Developer of optical coherence tomography for coronary functional evaluation 21Funding top 33%Talent top 38%Global bottom 36%Tech bottom 34% All 5 signals ▾Fundingtop 33% Talenttop 38% Globalbottom 36% Techbottom 34% Marketbottom 25% Funding: Raised $28.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $28M | 3 mo ago | Seed | Zhu Rui Founder & CEO | — | PHPLaravelBootstrap+11 | — | — |
| 36 | Hexaell Biotech Developer of therapeutic solutions for treating severe liver diseases 48Market top 39%Funding top 44%Global bottom 29% All 3 signals ▾Markettop 39% Fundingtop 44% Globalbottom 29% Market: 100 employees (top 20% of Life Sciences) Funding: Raised $27.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $27M | 16 mo ago | Series B | — | 100 | — | — | — |
| 37 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 7 mo ago | Series B | Rongkuan Hu Founder | — | — | — | — |
| 38 | Deep Intelligent Pharma Developer of AI-based drug development platform 62Funding top 26%Talent top 28%AI top 30%Moat top 39% All 7 signals ▾Fundingtop 26% Talenttop 28% AItop 30% Moattop 39% Marketbottom 49% Techbottom 43% Globalbottom 29% Funding: Raised $21.6M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 62/100 | $22M | 4 mo ago | Series E | — | 100 | Node.jsAnt DesignReact+9 | — | — |
| 39 | CNRT Provider of medical isotopes for diagnosis and treatment of malignant tumors 62Talent top 28%Funding top 33%Market top 40%Moat top 42% All 5 signals ▾Talenttop 28% Fundingtop 33% Markettop 40% Moattop 42% Globalbottom 36% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $16.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $17M | 2 mo ago | Series E | Maoliang Li Co-Founder & Chairman | 100 | — | — | — |
| 40 | Pulnovo Medical Developer of a medical device for the treatment of pulmonary hypertension 62Moat top 25%Patents top 31%Innovation top 33%Funding top 38% All 9 signals ▾Moattop 25% Patentstop 31% Innovationtop 33% Fundingtop 38% Markettop 39% Growthtop 48% Talentbottom 49% Globalbottom 43% Newsbottom 34% Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents Patents: 38 patents matched (strict assignee match) · 27 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $15M | 15 mo ago | Series C | Jessie Lian CEO | 100 | — | 38 patents Catheter-based radiofrequency ablation of the pulmonary artery for heart‑failure therapy | 1 partnership |
| 41 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 11 mo ago | Series A | — | 60 | — | — | — |
| 42 | Qiyuan Biological Developer of drugs for the treatment of autoimmune diseases 22Funding top 41%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 41% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 9 mo ago | Series B | Ding Shizhe CEO | — | — | — | — |
| 43 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 9 mo ago | Series B | Yuxuan Wu Founder & CEO | — | — | — | — |
| 44 | Pulsecare Medical Technology Developer of medical device solutions for heart and vascular care 22Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 7 mo ago | Series A | Javen Tan CEO | — | — | — | — |
| 45 | Milestone Biotechnologies Company solutions for various applications including single-cell mutation analysis, CDMO services and… 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $13.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 17 mo ago | Series A | Zhang Jinbao Founder & CEO | — | — | — | — |
| 46 | Iongen Therepeutics Developer of novel analgesic drugs targeting Nav1.8 and Nav1.7 ion channels 60Funding top 42%Talent top 45%Global bottom 48% All 3 signals ▾Fundingtop 42% Talenttop 45% Globalbottom 48% Funding: Raised $13.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 60/100 | $14M | 17 mo ago | Seed | Yang Yong Co-Founder | — | — | — | — |
| 47 | Convergen Pharmaceuticals Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech… 48Funding top 41%AI top 45%Talent bottom 45%Global bottom 33% All 4 signals ▾Fundingtop 41% AItop 45% Talentbottom 45% Globalbottom 33% Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: generative ai rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 6 mo ago | Seed | Jinquan Sun Co-Founder & CEO | — | — | — | — |
| 48 | Chengdu Zhongke Aoge Biotechnology Developer of xenotransplantation technology for research purposes 32Talent top 38%Market bottom 44%Funding bottom 43%Global bottom 36% All 4 signals ▾Talenttop 38% Marketbottom 44% Fundingbottom 43% Globalbottom 36% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Market: 30 employees (top 50% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 9 mo ago | Series A | Pan Dengke Founder | 30 | — | — | — |
| 49 | Nanochap Bio-medical devices developer 69Talent top 35%Market top 39%Funding top 42%Global bottom 36% All 4 signals ▾Talenttop 35% Markettop 39% Fundingtop 42% Globalbottom 36% Talent: Analyst team rating 4/5 · 2 named leaders on record Market: 100 employees (top 25% of High Tech) rank vs industry peers · Fliar Intelligence Index 69/100 | $4M | 1 mo ago | Series B | Jiawei Yang Co-Founder & CEO | 100 | — | — | 1 job opening |
| 50 | Beta Pharmaceutical Technology Developer of disease diagnostic reagents 55Innovation top 32%Moat top 32%Patents top 33%Talent bottom 45% All 6 signals ▾Innovationtop 32% Moattop 32% Patentstop 33% Talentbottom 45% Fundingbottom 43% Globalbottom 29% Innovation: 49 patents (top 48% of patent-holders) · 42 filings since 2022 vs 7 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $1M | 7 mo ago | Series C | Zhu Chenggu CEO | — | — | 49 patents Antiviral and protein‑misfolding therapeutics using PI4K inhibitors and arsenic‑based compounds | — |
Top 12 Life Sciences companies in China
#1
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees$400Mraised▾
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees
Developer of drugs to treat autoimmune, cancer, and infectious diseases. The company has developed its proprietary Trimer-Tag technology to develop novel, trimerized fusion-protein therapies. The trimerized fusion proteins have been shown to have a much better binding and therapeutic response. The company's drug pipeline include SCB-808, in a ready-for-injection prefilled syringe formulation and SCB-313 for Oncology.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 13%Market
top 25%Global
top 44%Moat
top 48%News
bottom 32%Tech
bottom 24%Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom
Global: Serving 4 countries incl. United States, China, United Kingdom · Investors from 3 countries beyond China
Audience (LinkedIn): 8k LinkedIn followers — 10.9% of this cohort's audience
Funding rounds
- Mar 2026Post IPO$3.6M
- Apr 2024Post IPO$320.7K
- May 2023Post IPO$48.9M
- Dec 2022Post IPO$64.4M
Investors
GL Ventures, Temasek, Delos Capital, Orbimed, Oceanpine Capital, Qiaojing Capital
Tech stack
PhpTengineSwiperJqueryHsts
#2
Series D · Shanghai, Shanghai · founded 2021$94.3Mraised▾
Series D · Shanghai, Shanghai · founded 2021
Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Patents
top 33%Growth
top 35%Innovation
top 45%Moat
top 47%Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) · Last round Series D (May 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Patents: 24 patents matched (strict assignee match) · 24 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 7k LinkedIn followers — 9.9% of this cohort's audience
Activity (LinkedIn): 1 awards · 1 expansions announced in 12 mo
Funding rounds
- May 2026Series D$110M
- May 2026Conventional Debt$40M
- Sep 2025Series C$50M
- Sep 2025Conventional Debt$27M
Founders & team
Investors
Prosperity7 Ventures, Sky9 Capital, Summer Capital, Chengwei Capital, Junson Capital, Guanghua Wutong Fund
Tech stack
Alibaba Cloud CdnAnimate.CssBaidu Analytics (百度统计)BootstrapJqueryNginx
#3
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees$255Mraised▾
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees
Developer of small molecules for the treatment of multiple diseases. It offers pipeline of drug candidates which include Ritonavir for Covid, Ravidasvir for HCV, ASC22 for HIV, ASC40 for NASH, acne, solid tumor, breast cancer, and others.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 19%Product
top 30%Moat
top 31%Innovation
top 34%Talent
bottom 49%Market
bottom 42%Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Feb 2026)
Product: 6 distinct product lines · Company stage: Series B
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Feb 2026Post IPO$107.9M
- Jan 2017Series B$100M
- Dec 2015Series B$20M
- Sep 2015Series B$35M
Founders & team
Investors
CBC Group, Tasly, Pavilion Capital Partners, Goldman Sachs, Qianhai Equity Investment Fund, Hangzhou Binjiang Investment Holding
#4
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Series D · Pudong, Shanghai · founded 2015 · 150 employees
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 16%Patents
top 27%Moat
top 28%Innovation
top 34%News
top 36%Market
top 37%Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series D (Apr 2026)
Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers — 4.1% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: TCE Senior Scientist, Senior Scientist (In vivo CAR-T)
Funding rounds
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
Founders & team
Investors
RTW Investments, Qatar Investment Authority, Qiming Venture Partners, C&D, Quan Capital, Sinopharm Capital
#5
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Series C · Suzhou, Jiangsu · founded 2017
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Market
bottom 49%Global
bottom 48%Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series C (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 131 LinkedIn followers
Funding rounds
- May 2026Series C$50M
- Mar 2025Series B$12M
Founders & team
Investors
Shenzhen Capital Group, Morningside, Suzhou Industrial Park Leading Venture Capital, Hefei Sci-Tec, Orbimed, TCG Crossover
#6
Series B · Shanghai, Shanghai · founded 2018$262Mraised▾
Series B · Shanghai, Shanghai · founded 2018
Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 20%Growth
top 35%Talent
bottom 49%Moat
bottom 48%Tech
bottom 40%Global
bottom 38%Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Dec 2025)
Growth: Fresh capital in last 24 mo
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Dec 2025Series B$108M
- Apr 2024Series A$62M
- Nov 2020Series A$200M
Founders & team
Investors
Medicxi, WuXi AppTec, Matrix Partners China, Boyu Capital, Sequoia Capital China, Temasek
Tech stack
CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365
#7
Series D · Shenzhen, Guangdong Province · founded 2019$188.8Mraised▾
Series D · Shenzhen, Guangdong Province · founded 2019
Developer of medical robotic devices for rehabilitation and surgery. The company is developing medical robotic devices and equipment which enable physicians to improve the efficiency of surgical operations.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 16%Moat
top 31%Talent
bottom 49%News
bottom 41%Global
bottom 38%Market
bottom 28%Funding: Raised $189M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers — 7.6% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Nov 2025Series D$200M
- Jan 2025Series C$70M
- Jul 2023Series C$110.4M
- Nov 2021Series B$78.4M
Founders & team
Investors
Meituan, Dragon Ball Game, Lilly Asia Ventures, New World Development, Qiming Venture Partners, K2VC
Tech stack
Baidu Analytics (百度统计)GsapJqueryLayuiNginxOpen Graph
#8
Series A · Shenzhen, Guangdong Province · founded 2021$42.9Mraised▾
Series A · Shenzhen, Guangdong Province · founded 2021
Develope rof AI-based platform for cancer immunotherapy. It provides a Meta 10 Metabolism-enhanced cell treatment platform that encourages the metabolic reprogramming of exhausted T lymphocytes by oxidative phosphorylation, restoring their ability to proliferate and kill malignancies.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
AI
top 30%Talent
top 38%Funding
top 39%Global
bottom 29%Market
bottom 25%Tech
bottom 15%AI: Classified as an AI company · Product described with: ai-based
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $42.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Mar 2026)
Audience (LinkedIn): 3k LinkedIn followers — 4.0% of this cohort's audience
Activity (LinkedIn): 1 awards · 1 expansions announced in 12 mo
Funding rounds
- Mar 2026Series A$29M
- Nov 2024Series A$13.9M
Founders & team
Investors
Jingtai Technology, Junyiinvestment, FUHO Capital Management, Zhongying Venture Capital, Tailong Investment, Zhongshan Venture Capital
Tech stack
Apache Http ServerBabelCore-JsPhp
#9
Series A · Shanghai, Shanghai · founded 2020 · 22 employees$100Mraised▾
Series A · Shanghai, Shanghai · founded 2020 · 22 employees
Developer of therapeutic solutions for the treatment of central nervous system disorders.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Tech
bottom 45%Global
bottom 36%Market
bottom 33%Funding: Raised $100M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series A (Dec 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 3k LinkedIn followers — 4.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. Novartis Pharma AG) announced in 12 mo
Funding rounds
- Dec 2025Series A$53M
- Nov 2025Grant (prize money)$5M
- Dec 2020Series A$100M
Founders & team
Investors
Arch Venture Partners, Boyu Capital, General Atlantic, Sequoia Capital, TF Capital, LAV
#10
Series D · Lanzhou, Gansu · founded 2016 · 100 employees$84.8Mraised▾
Series D · Lanzhou, Gansu · founded 2016 · 100 employees
Developer of vaccines for infectious diseases. It offers an adjuvant platform, recombinant protein expression platform, and mRNA platform for developing preventive and therapeutic vaccines for influenza vaccine, rabies vaccine, rotavirus vaccine, and herpes zoster vaccine.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Market
top 40%Moat
top 42%Talent
bottom 49%Global
bottom 36%Funding: Raised $84.8M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Series D (Dec 2025)
Market: 100 employees (top 20% of Life Sciences)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Dec 2025Series D—
- Jul 2024Series C$41.3M
- Feb 2024Series C$41.9M
- Jul 2022Series B—
Founders & team
Investors
China Life Insurance, Sherpa Healthcare Partners, Hillhouse, Xinshang Capital, Korea Investment Partners, Qianhai Ark Asset Management
#11
Seed · Shenzhen, Guangdong Province · founded 2012$28.5Mraised▾
Seed · Shenzhen, Guangdong Province · founded 2012
Developer of optical coherence tomography for coronary functional evaluation. The company focuses on the development of medical devices for minimally invasive interventional diagnosis and treatment using laser technology for clinical use.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 33%Talent
top 38%Global
bottom 36%Tech
bottom 34%Market
bottom 25%Funding: Raised $28.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 2 countries beyond China
Audience (LinkedIn): 868 LinkedIn followers
Funding rounds
- Mar 2026Seed$14.5M
- Mar 2024Seed$14M
Founders & team
Investors
Zhejiang Huarui Investment Holdings, Guangzhou Industrial Investment Group, HSG, BlueRun Ventures, Ant Group, CDH
Tech stack
Apache Http ServerBootstrapFancyboxFont AwesomeGoogle AnalyticsGoogle Tag Manager
#12
Series B · Hangzhou, Zhejiang · founded 2017 · 100 employees$29.4Mraised▾
Series B · Hangzhou, Zhejiang · founded 2017 · 100 employees
Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions. The company's products include exoskeleton robotics, robot joint modules, mecanum wheel modules, and servo motion control solutions. It also operate a rehabilitation cloud platform that supports remote rehabilitation guidance and a rehabilitation intelligence evaluation system that generates detailed assessment reports for users to track progress and effectiveness.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 36%Market
top 42%Growth
top 45%Talent
bottom 49%Global
bottom 48%Tech
bottom 35%Funding: Raised $29.4M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Mar 2026)
Market: 100 employees (top 20% of Life Sciences) · Top-5,000,000 web property
Growth: Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 360 LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Grupo Laços and the China Trade Center Group) announced in 12 mo
Funding rounds
- Mar 2026Series B$13.7M
- Feb 2022Series A$15.7M
- Mar 2021Seed—
Founders & team
Investors
Lanchi Venture Capital, Poly Development Holdings, Anxin Securities, Fortune Capital, Asia Business Capital, Hangzhou Capital
Tech stack
Baidu Analytics (百度统计)Cart FunctionalityFont AwesomeFullpage.JsGoogle AnalyticsGoogle Tag Manager
Funding & investor landscape
$33.5Btotal disclosed funding
444companies funded
745disclosed rounds
7rounds last 90 days
Most active investors
Notable founders
HH Ting
Co-Founder And Chief Strategy Officer · Full-Life Technologies
HongHoi Ting
Co-Founder · Full-Life Technologies
Jinzi Wu
Founder & CEO · Ascletis
He Xiaowen
Co-Founder · OriCell Therapeutics
Xiaohu Zhang
Co-Founder & CEO · Accropeutics
Sudan He
Co-Founder · Accropeutics
George Chen
Founder & CEO · D3 Bio
Zerui Wang
Co-Founder · Cornerstone Robotics
Li Tang
Co-Founder · Leman Biotech
Yugang Guo
Co-Founder · Leman Biotech
Min Li
Founder & CEO · SciNeuro
Dexiang Chen
Founder · MAXVAX Biotechnology
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · China
How research on Biotechnology is moving in China
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,865 China-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and softening — the enthusiastic (strongly-positive) share moved 52% → 49% across 2008–2026.
top research entities
- Chinese Academy of Sciences263
- Chinese Academy of Agricultural Sciences227
- Ministry of Agriculture and Rural Affairs168
- China Agricultural University159
- Huazhong Agricultural University138
leading researchers
Yong Li · Ying Liu · Jing Wang · Yan Zhang · Yang Li · Xi Zhang · Yu Wang · Wei Wang
▲
Breakthroughs1,753 · 30%
▼ 40%→29% share
▼0.7× share momentum0 median citations89% since 2021mostly methods-led
Gene-level breakthrough discovery is cooling — field-share fell 40%→29% despite Gene papers surging 4→218.
rising sub-themes (early→recent)
- Gene4→218
- Gene knockdown3→73
- Transcriptome1→62
- Detection limit1→59
- Mutant3→56
Newly emergingIdentification (biology) 0→52 · Nucleic acid 0→51 · Cell culture 0→42
Landmark Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Inv · 5,748 cites
◆
Advancements2,680 · 46%
▲ 34%→47% share
▲1.4× share momentum0 median citations94% since 2021mostly empirical
Functional genomics advancement is intensifying — Transcriptome, Downregulation/upregulation, and Apoptosis papers collectively grew from near-zero to 461.
rising sub-themes (early→recent)
- Gene9→275
- Gene knockdown1→166
- Downregulation and upregulation2→161
- Apoptosis6→129
- Transcription factor3→77
Newly emergingTranscriptome 0→175 · Fermentation 0→126 · Metabolomics 0→89
Landmark Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV · 3,380 cites
▼
Concerns674 · 11%
11%→11% share
▲1.0× share momentum0 median citations92% since 2021mostly reviews
Antibiotic-resistance and food-safety concerns are newly intensifying — Agriculture rose 6→68 and Food safety emerged at 21 papers.
rising sub-themes (early→recent)
- Agriculture6→68
- Antibiotic resistance1→43
- Resistance (ecology)2→33
- Gene2→32
- Synthetic biology1→30
Newly emergingHuman health 0→33 · Quality (philosophy) 0→22 · Food safety 0→21
Landmark Antibiotic resistance: a rundown of a global crisis · 2,496 cites
RESEARCH HOTSPOTS · China
Where biotechnology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Beijing643 · +0.54
Shanghai439 · +0.54
Guangzhou/Shenzhen355 · +0.58
Nanjing332 · +0.50
Hangzhou215 · +0.53
Wuhan162 · +0.60
Harbin84 · +0.61
Hefei49 · +0.61
PATENT SIGNAL · China
Who's filing biotechnology patents in China
China biotechnology patent filing is accelerating — 58,925 filings from 8,000 assignees (2016–2025), led by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine, UNIV Jiangnan; annual filings 1737→10545.
58,925 filings8,000 assigneespeak 10545/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Shanghai Hengrui Pharmaceutical1154
- Jiangsu Hengrui Medicine1027
- UNIV Jiangnan1000
- Innovent Biologics Suzhou666
- UNIV Tsinghua627
- Jiangsu Hengrui Pharmaceuticals594
- UNIV Xiamen575
- UNIV Beijing549
Common questions
How many Life Sciences companies are there in China?
Radar tracks 1538 indexable Life Sciences companies headquartered in China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in China?
The Life Sciences companies in China on this list have raised a combined $33.5B in disclosed equity funding across 444 funded companies.
Which is the highest-funded Life Sciences company in China?
Abogen Biosciences is the highest-funded Life Sciences company in China, with $1.1B in disclosed equity funding.
How many Life Sciences companies in China are funded?
444 of the 1538 Life Sciences companies in China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in China?
8 Life Sciences companies in China on this list are valued at $1B or more.
Who are the top investors in China Life Sciences companies?
The most active investors in China Life Sciences companies on this list include Qiming Venture Partners, Hillhouse, Lilly Asia Ventures, Yuanbio Venture Capital, Legend Capital.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.